Intrinsic value of EXACT Sciences - EXAS

Previous Close

$48.68

  Intrinsic Value

$80.83

stock screener

  Rating & Target

str. buy

+66%

Previous close

$48.68

 
Intrinsic value

$80.83

 
Up/down potential

+66%

 
Rating

str. buy

We calculate the intrinsic value of EXAS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 5.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  426
  658
  983
  1,427
  2,013
  2,767
  3,715
  4,878
  6,276
  7,928
  9,844
  12,036
  14,507
  17,260
  20,295
  23,608
  27,195
  31,049
  35,164
  39,535
  44,155
  49,020
  54,127
  59,471
  65,054
  70,875
  76,938
  83,245
  89,804
  96,620
Variable operating expenses, $m
  295
  454
  678
  983
  1,387
  1,905
  2,557
  3,357
  4,319
  5,454
  6,770
  8,277
  9,977
  11,870
  13,958
  16,236
  18,703
  21,353
  24,184
  27,189
  30,367
  33,713
  37,224
  40,900
  44,740
  48,743
  52,912
  57,250
  61,761
  66,449
Fixed operating expenses, $m
  207
  212
  217
  221
  226
  231
  236
  242
  247
  252
  258
  264
  269
  275
  281
  288
  294
  300
  307
  314
  321
  328
  335
  342
  350
  357
  365
  373
  382
  390
Total operating expenses, $m
  502
  666
  895
  1,204
  1,613
  2,136
  2,793
  3,599
  4,566
  5,706
  7,028
  8,541
  10,246
  12,145
  14,239
  16,524
  18,997
  21,653
  24,491
  27,503
  30,688
  34,041
  37,559
  41,242
  45,090
  49,100
  53,277
  57,623
  62,143
  66,839
Operating income, $m
  -77
  -9
  88
  222
  400
  631
  921
  1,279
  1,711
  2,221
  2,816
  3,495
  4,261
  5,115
  6,056
  7,085
  8,198
  9,395
  10,674
  12,032
  13,468
  14,980
  16,567
  18,229
  19,965
  21,775
  23,660
  25,622
  27,661
  29,782
EBITDA, $m
  -63
  11
  117
  262
  456
  707
  1,023
  1,412
  1,881
  2,435
  3,079
  3,816
  4,648
  5,575
  6,598
  7,715
  8,924
  10,224
  11,613
  13,088
  14,647
  16,289
  18,012
  19,817
  21,702
  23,667
  25,714
  27,844
  30,059
  32,361
Interest expense (income), $m
  0
  0
  3
  6
  12
  19
  28
  40
  55
  73
  95
  121
  152
  186
  226
  269
  317
  370
  426
  487
  552
  622
  695
  772
  852
  937
  1,025
  1,117
  1,213
  1,313
  1,417
Earnings before tax, $m
  -77
  -12
  82
  210
  382
  603
  882
  1,225
  1,638
  2,126
  2,695
  3,343
  4,074
  4,889
  5,787
  6,767
  7,829
  8,969
  10,187
  11,480
  12,846
  14,285
  15,796
  17,377
  19,028
  20,750
  22,543
  24,408
  26,348
  28,365
Tax expense, $m
  0
  0
  22
  57
  103
  163
  238
  331
  442
  574
  728
  903
  1,100
  1,320
  1,563
  1,827
  2,114
  2,422
  2,750
  3,099
  3,469
  3,857
  4,265
  4,692
  5,138
  5,602
  6,087
  6,590
  7,114
  7,659
Net income, $m
  -77
  -12
  60
  154
  278
  440
  644
  894
  1,195
  1,552
  1,967
  2,440
  2,974
  3,569
  4,225
  4,940
  5,715
  6,547
  7,436
  8,380
  9,378
  10,428
  11,531
  12,685
  13,890
  15,147
  16,456
  17,818
  19,234
  20,706

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  387
  598
  895
  1,298
  1,832
  2,518
  3,380
  4,438
  5,711
  7,213
  8,957
  10,951
  13,200
  15,706
  18,467
  21,481
  24,745
  28,252
  31,997
  35,974
  40,178
  44,605
  49,251
  54,114
  59,194
  64,491
  70,007
  75,746
  81,714
  87,917
Adjusted assets (=assets-cash), $m
  387
  598
  895
  1,298
  1,832
  2,518
  3,380
  4,438
  5,711
  7,213
  8,957
  10,951
  13,200
  15,706
  18,467
  21,481
  24,745
  28,252
  31,997
  35,974
  40,178
  44,605
  49,251
  54,114
  59,194
  64,491
  70,007
  75,746
  81,714
  87,917
Revenue / Adjusted assets
  1.101
  1.100
  1.098
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
  1.099
Average production assets, $m
  114
  176
  263
  381
  537
  739
  992
  1,302
  1,676
  2,117
  2,628
  3,214
  3,873
  4,609
  5,419
  6,303
  7,261
  8,290
  9,389
  10,556
  11,790
  13,088
  14,452
  15,879
  17,369
  18,924
  20,542
  22,226
  23,978
  25,798
Working capital, $m
  16
  24
  36
  53
  74
  102
  137
  180
  232
  293
  364
  445
  537
  639
  751
  874
  1,006
  1,149
  1,301
  1,463
  1,634
  1,814
  2,003
  2,200
  2,407
  2,622
  2,847
  3,080
  3,323
  3,575
Total debt, $m
  51
  119
  214
  344
  516
  737
  1,014
  1,355
  1,765
  2,249
  2,810
  3,452
  4,176
  4,983
  5,872
  6,843
  7,894
  9,023
  10,229
  11,509
  12,863
  14,289
  15,785
  17,351
  18,986
  20,692
  22,468
  24,316
  26,238
  28,235
Total liabilities, $m
  125
  193
  288
  418
  590
  811
  1,088
  1,429
  1,839
  2,323
  2,884
  3,526
  4,250
  5,057
  5,946
  6,917
  7,968
  9,097
  10,303
  11,584
  12,937
  14,363
  15,859
  17,425
  19,060
  20,766
  22,542
  24,390
  26,312
  28,309
Total equity, $m
  263
  406
  607
  880
  1,242
  1,707
  2,292
  3,009
  3,872
  4,891
  6,073
  7,425
  8,950
  10,648
  12,521
  14,564
  16,777
  19,155
  21,694
  24,390
  27,241
  30,242
  33,392
  36,689
  40,133
  43,725
  47,465
  51,356
  55,402
  59,607
Total liabilities and equity, $m
  388
  599
  895
  1,298
  1,832
  2,518
  3,380
  4,438
  5,711
  7,214
  8,957
  10,951
  13,200
  15,705
  18,467
  21,481
  24,745
  28,252
  31,997
  35,974
  40,178
  44,605
  49,251
  54,114
  59,193
  64,491
  70,007
  75,746
  81,714
  87,916
Debt-to-equity ratio
  0.190
  0.290
  0.350
  0.390
  0.420
  0.430
  0.440
  0.450
  0.460
  0.460
  0.460
  0.460
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
Adjusted equity ratio
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -77
  -12
  60
  154
  278
  440
  644
  894
  1,195
  1,552
  1,967
  2,440
  2,974
  3,569
  4,225
  4,940
  5,715
  6,547
  7,436
  8,380
  9,378
  10,428
  11,531
  12,685
  13,890
  15,147
  16,456
  17,818
  19,234
  20,706
Depreciation, amort., depletion, $m
  14
  20
  28
  40
  56
  76
  101
  132
  170
  214
  263
  321
  387
  461
  542
  630
  726
  829
  939
  1,056
  1,179
  1,309
  1,445
  1,588
  1,737
  1,892
  2,054
  2,223
  2,398
  2,580
Funds from operations, $m
  -63
  8
  88
  194
  334
  516
  745
  1,026
  1,365
  1,766
  2,230
  2,762
  3,362
  4,030
  4,766
  5,571
  6,441
  7,376
  8,375
  9,436
  10,557
  11,737
  12,976
  14,273
  15,627
  17,040
  18,510
  20,041
  21,632
  23,286
Change in working capital, $m
  6
  9
  12
  16
  22
  28
  35
  43
  52
  61
  71
  81
  91
  102
  112
  123
  133
  143
  152
  162
  171
  180
  189
  198
  207
  215
  224
  233
  243
  252
Cash from operations, $m
  -69
  0
  76
  177
  313
  488
  710
  983
  1,314
  1,705
  2,159
  2,681
  3,270
  3,928
  4,654
  5,448
  6,308
  7,234
  8,223
  9,274
  10,386
  11,557
  12,787
  14,075
  15,421
  16,824
  18,286
  19,807
  21,389
  23,034
Maintenance CAPEX, $m
  -7
  -11
  -18
  -26
  -38
  -54
  -74
  -99
  -130
  -168
  -212
  -263
  -321
  -387
  -461
  -542
  -630
  -726
  -829
  -939
  -1,056
  -1,179
  -1,309
  -1,445
  -1,588
  -1,737
  -1,892
  -2,054
  -2,223
  -2,398
New CAPEX, $m
  -43
  -62
  -87
  -118
  -157
  -201
  -253
  -311
  -373
  -441
  -512
  -585
  -660
  -735
  -810
  -885
  -958
  -1,029
  -1,099
  -1,167
  -1,234
  -1,299
  -1,363
  -1,427
  -1,491
  -1,554
  -1,619
  -1,684
  -1,751
  -1,820
Cash from investing activities, $m
  -50
  -73
  -105
  -144
  -195
  -255
  -327
  -410
  -503
  -609
  -724
  -848
  -981
  -1,122
  -1,271
  -1,427
  -1,588
  -1,755
  -1,928
  -2,106
  -2,290
  -2,478
  -2,672
  -2,872
  -3,079
  -3,291
  -3,511
  -3,738
  -3,974
  -4,218
Free cash flow, $m
  -119
  -74
  -28
  33
  118
  233
  383
  574
  810
  1,096
  1,436
  1,833
  2,289
  2,806
  3,383
  4,022
  4,720
  5,479
  6,295
  7,168
  8,097
  9,079
  10,115
  11,203
  12,342
  13,533
  14,775
  16,069
  17,416
  18,816
Issuance/(repayment) of debt, $m
  46
  68
  95
  130
  172
  221
  278
  341
  410
  484
  562
  642
  724
  807
  889
  971
  1,051
  1,129
  1,206
  1,281
  1,354
  1,425
  1,496
  1,566
  1,636
  1,706
  1,776
  1,848
  1,922
  1,997
Issuance/(repurchase) of shares, $m
  176
  155
  141
  120
  83
  25
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  222
  223
  236
  250
  255
  246
  278
  341
  410
  484
  562
  642
  724
  807
  889
  971
  1,051
  1,129
  1,206
  1,281
  1,354
  1,425
  1,496
  1,566
  1,636
  1,706
  1,776
  1,848
  1,922
  1,997
Total cash flow (excl. dividends), $m
  104
  149
  208
  283
  373
  479
  661
  914
  1,220
  1,580
  1,997
  2,475
  3,013
  3,612
  4,272
  4,992
  5,771
  6,608
  7,501
  8,449
  9,450
  10,505
  11,611
  12,769
  13,978
  15,239
  16,551
  17,917
  19,337
  20,813
Retained Cash Flow (-), $m
  -176
  -155
  -201
  -274
  -362
  -465
  -584
  -717
  -863
  -1,019
  -1,182
  -1,352
  -1,525
  -1,699
  -1,872
  -2,044
  -2,213
  -2,378
  -2,539
  -2,696
  -2,850
  -3,001
  -3,150
  -3,297
  -3,444
  -3,591
  -3,740
  -3,891
  -4,046
  -4,205
Prev. year cash balance distribution, $m
  356
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  36
  57
  88
  132
  191
  270
  371
  498
  654
  841
  1,062
  1,319
  1,613
  1,944
  2,313
  2,720
  3,163
  3,644
  4,161
  4,712
  5,298
  5,917
  6,569
  7,253
  7,969
  8,717
  9,497
  10,310
  11,155
  12,034
Cash available for distribution, $m
  284
  -6
  7
  9
  11
  14
  76
  197
  357
  561
  815
  1,123
  1,488
  1,914
  2,400
  2,948
  3,559
  4,230
  4,962
  5,752
  6,600
  7,503
  8,461
  9,471
  10,534
  11,647
  12,811
  14,026
  15,291
  16,608
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  272
  -5
  6
  8
  9
  10
  52
  123
  205
  294
  387
  479
  566
  642
  705
  749
  774
  779
  764
  731
  683
  623
  555
  482
  410
  340
  275
  217
  167
  125
Current shareholders' claim on cash, %
  90.3
  85.3
  82.4
  80.8
  80.0
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9
  79.9

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

FINANCIAL RATIOS  of  EXACT Sciences (EXAS)

Valuation Ratios
P/E Ratio -32.1
Price to Sales 54.2
Price to Book 16
Price to Tangible Book
Price to Cash Flow -41.3
Price to Free Cash Flow -37
Growth Rates
Sales Growth Rate 153.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -31.8%
Cap. Spend. - 3 Yr. Gr. Rate 10.8%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 1.5%
Total Debt to Equity 1.5%
Interest Coverage 0
Management Effectiveness
Return On Assets -45.1%
Ret/ On Assets - 3 Yr. Avg. -45.1%
Return On Total Capital -49.6%
Ret/ On T. Cap. - 3 Yr. Avg. -48.9%
Return On Equity -50.5%
Return On Equity - 3 Yr. Avg. -49.6%
Asset Turnover 0.3
Profitability Ratios
Gross Margin 54.5%
Gross Margin - 3 Yr. Avg. -19%
EBITDA Margin -157.6%
EBITDA Margin - 3 Yr. Avg. -1780.7%
Operating Margin -170.7%
Oper. Margin - 3 Yr. Avg. -1860.3%
Pre-Tax Margin -168.7%
Pre-Tax Margin - 3 Yr. Avg. -1857.9%
Net Profit Margin -168.7%
Net Profit Margin - 3 Yr. Avg. -1857.9%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

EXAS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the EXAS stock intrinsic value calculation we used $266 million for the last fiscal year's total revenue generated by EXACT Sciences. The default revenue input number comes from 2017 income statement of EXACT Sciences. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our EXAS stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for EXAS is calculated based on our internal credit rating of EXACT Sciences, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of EXACT Sciences.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of EXAS stock the variable cost ratio is equal to 69.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $203 million in the base year in the intrinsic value calculation for EXAS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for EXACT Sciences.

Corporate tax rate of 27% is the nominal tax rate for EXACT Sciences. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the EXAS stock is equal to 13.4%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for EXAS are equal to 26.7%.

Life of production assets of 10 years is the average useful life of capital assets used in EXACT Sciences operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for EXAS is equal to 3.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $520 million for EXACT Sciences - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 116 million for EXACT Sciences is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of EXACT Sciences at the current share price and the inputted number of shares is $5.6 billion.

RELATED COMPANIES Price Int.Val. Rating
DGX Quest Diagnost 109.54 103.25  hold
CGIX Cancer Genetic 1.09 0.14  str.sell
NVTA Invitae 10.48 0.21  str.sell
NEO NeoGenomics 12.55 1.56  str.sell
ENZ Enzo Biochem 4.06 13.53  str.buy
TROV TrovaGene 0.800 0.05  str.sell

COMPANY NEWS

▶ Exact Sciences begins work on new HQ in Madison's University Research Park   [Aug-15-18 12:36PM  American City Business Journals]
▶ GlycoMimetics Stock Has Substantial Upside   [Aug-10-18 03:17PM  InvestorPlace]
▶ Is Exact Sciences a Buy on the Dip?   [Aug-06-18 09:36AM  Motley Fool]
▶ Exact Sciences: 2Q Earnings Snapshot   [Aug-01-18 05:37PM  Associated Press]
▶ 3 'Strong Buy' Healthcare Stocks Poised to Surge   [Jul-25-18 01:10PM  TheStreet.com]
▶ Why Exact Sciences Shares Are Rallying 13.8% in 2018   [Jul-07-18 07:15AM  Motley Fool]
▶ 3 Small Cap Stocks That Can Thrive Amid a Trade War   [Jun-21-18 06:00AM  Investopedia]
▶ This Biotech Said It Can Detect Liver Cancer In Your Blood And Broke Out   [Jun-06-18 04:10PM  Investor's Business Daily]
▶ Where Will Exact Sciences Corporation Be in 5 Years?   [May-29-18 08:18AM  Motley Fool]
▶ 4 Biotech Stocks Set to Rise By 14% or More   [May-14-18 06:00AM  Investopedia]
▶ Exact Sciences teams with Vince Lombardi foundation in fight against colon cancer   [May-03-18 12:36PM  American City Business Journals]
▶ [$$] Exact Sciences: A Big Opportunity?   [May-02-18 04:08PM  Barrons.com]
▶ Why Exact Sciences Is Soaring Today   [12:30PM  Motley Fool]
▶ Exact Sciences: 1Q Earnings Snapshot   [05:06AM  Associated Press]
▶ Exact Sciences revenue jumps 87% in first quarter, topping consensus   [Apr-26-18 05:11PM  American City Business Journals]
▶ Don't Get Greedy With Exact Sciences Corporation Stock   [Apr-25-18 06:02AM  Motley Fool]
▶ Is Exact Sciences Corp. Still a Buy in 2018?   [Apr-08-18 09:31AM  Motley Fool]
▶ Biotech's Exact Sciences Seen Plunging 25%   [Apr-06-18 02:53PM  Investopedia]
▶ BTIG Expects 55% Upside In Exact Sciences   [Apr-03-18 03:38PM  Benzinga]
▶ Exact Sciences names president to lead Cologuard product   [Mar-20-18 05:19PM  American City Business Journals]
▶ Exact Sciences Corporations (NASDAQ:EXAS) Profit Outlook   [Mar-14-18 10:54AM  Simply Wall St.]
▶ Exact Sciences finds winning combo in Jerry Kelly and the PGA Tour Champions   [Mar-09-18 01:55PM  American City Business Journals]
▶ Here's Why Exact Sciences Shares Fell 10.3% in February   [Mar-06-18 08:00PM  Motley Fool]
▶ This Biotech's Outlook Is Feeling The Flu Is It Just A 'Blip'?   [Feb-23-18 04:48PM  Investor's Business Daily]
▶ Exact Sciences reports 4Q loss   [Feb-22-18 05:00PM  Associated Press]
▶ These 3 Stocks Have Doubled Investors' Money   [Jan-23-18 07:31AM  Motley Fool]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.